Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 29.8 kDa. The protein migrates as 40-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human TROP-2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human TROP-2, His Tag (Cat. No. TR2-H5223) is more than 90% and the molecular weight of this protein is around 33-50 kDa verified by SEC-MALS.
Immobilized Human TROP-2, His Tag (Cat. No. TR2-H5223) at 1 μg/mL (100 μL/well) can bind Mouse Monoclonal Antibody Against Human TROP-2, Mouse IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Sacituzumab govitecan | IMMU0132; GS-0132; IMMU-0132; IMMU-132; TROP-2-SN-38 | Approved | Immunomedics Inc, Gilead Sciences Inc | Trodelvy, 拓达维, TRODELVY | United States | Triple Negative Breast Neoplasms | Immunomedics Inc | 2020-04-22 | Brain metastases; Urinary Bladder Neoplasms; Klatskin Tumor; Breast Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms; Metastatic breast cancer; Esophageal Squamous Cell Carcinoma; Thyroid Carcinoma, Anaplastic; Endometrial Neoplasms; Thymoma; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Solid tumours; Neoplasms; Salivary Gland Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Glioblastoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; Liver Failure | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
SHR-A1921 | SHR-A1921; SHRA1921; SHR-1921 | Phase 3 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Salivary Gland Neoplasms; Breast Neoplasms; Brain metastases | Details |
OBI-992 | OBI-992 | Phase 2 Clinical | Obi Pharma Usa Inc | Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
HS-20105 | HS-20105; HS20105 | Phase 2 Clinical | Hansoh BioMedical R&D Company | Solid tumours | Details |
IBI130 | IBI130; IBI-130 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
Anti TROP2 antibody drug conjugate ADC(Fudan University) | Phase 2 Clinical | Fudan University | Triple Negative Breast Neoplasms | Details | |
9MW-2921 | 9MW2921; 9MW-2921 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours | Details |
MHB036C | MHB-036C | Phase 2 Clinical | Minghui Pharmaceutical Pty Ltd | Solid tumours | Details |
BAT-8008 | BAT8008; BAT-8008 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
DB-1305 | DB1305; BNT325; DB-1305; BNT-325 | Phase 2 Clinical | Duality Biologics Co Ltd | Solid tumours | Details |
BIO-106 | BIO-106 | Phase 2 Clinical | Hangzhou Baikai Biopharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
BL-M02D1 | Phase 2 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
LCB-84 | LCB-84 | Phase 2 Clinical | Legochem Biosciences Inc | Solid tumours | Details |
重组人源化抗Trop2单抗-SN38偶联物 | ESG-401; STI-3258 | Phase 2 Clinical | Shanghai Escugen Biotechnology Co Ltd, Tot Biopharm Co Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms | Details |
FDA018 Antibody Drug Conjugate | FDA018-ADC; FDA-018-ADC | Phase 2 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Neoplasm Metastasis | Details |
DAC-002 | DAC-002; JS-108 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma | Details |
MT-302 | MT-302 | Phase 1 Clinical | Myeloid Therapeutics Inc | Carcinoma; Colonic Neoplasms; Breast Neoplasms; Lung Neoplasms | Details |
This web search service is supported by Google Inc.